PureTech’s Celea Moves Toward Phase III IPF Study With New Funding
The company raised $180m and plans to launch a Phase III trial that will pit deupirfenidone against Roche’s Esbriet (pirfenidone), which has gone generic.
Scrip - July 2, 2026

United Buys Thymmune, Gaining Preclinical Thymic Cell Therapies
Privately held Thymmune received $140m upfront while United gains THY-100 in preclinical development for an ultra-rare condition called congenital athymia.
Scrip - July 2, 2026

Execs On The Move: June 22–26, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - July 2, 2026

Scientists Finally Define What ‘Gut Health’ Means
A new expert consensus defines "gut health" for the first time, and warns along the way that popular claims around microbiome test kits and "leaky gut" run ahead of the science.
HBW Insight - July 2, 2026

Roche’s Divarasib Wins First Test Beating KRAS Rivals In NSCLC
The Basel-based group says that the KRAS G12C inhibitor showed clinically meaningful improvements in progression-free survival compared with Amgen's Lumakras and BMS's Krazati in non-small cell lung cancer patients. But other rivals loom.
Scrip - July 2, 2026

How Western Biotechs Are Navigating The China Challenge
As the BIOSECURE Act and proposed investment-screening laws reshape competition, US biotechs debate whether to engage China's surging drug pipeline or differentiate against it, with no industry-wide consensus on the right approach.
In Vivo - July 2, 2026

Second Time Lucky For SB’s Byooviz? Relaunch Offers Fresh Start In US Lucentis Biosimilar Market
After Samsung Bioepis ended its US marketing alliance with Biogen for its Byooviz rival to Lucentis, the ranibizumab biosimilar has now been relaunched via new commercialization partner Harrow. But this is not the only Lucentis rival to have experienced such upheaval.
Generics Bulletin - July 2, 2026

UK Healthcare Cyberattacks Surge Tenfold In 2026, But Ransomware Stays Absent
UK healthcare cyberattacks have surged nearly tenfold in early 2026, yet no ransomware has detonated — SonicWall's data points to something potentially more calculated: systematic network reconnaissance targeting unpatched legacy systems and newly built patient portals simultaneously.
Medtech Insight - July 2, 2026

Global Medtech Guidance Tracker: June 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 60 documents have been posted on the tracker since its last update.
Medtech Insight - July 2, 2026

Terumo’s Global RelayPro Recall Tests Aortic Franchise Amid Record Year
Terumo is recalling about 7,000 RelayPro thoracic stent-grafts across 43 countries after four delivery-system failures, three linked to patient deaths during or following surgery. The FDA has deemed it Class I — its most serious — though causality is unconfirmed.
Medtech Insight - July 2, 2026

Japan Deal Strengthens EirGenix’s HER2 Biosimilar Story
EirGenix’s Japan licensing deal for EG1206A extends its HER2 biosimilar partnering strategy, adding a regional route to market while the company builds a broader oncology and CDMO operation.
Generics Bulletin - July 2, 2026

Aurobindo Begins Integration As It Completes Lannett Acquisition
With a recent FTC approval in hand, Aurobindo has completed its deal to acquire Lannett in the US. The completion means that integration activities can begin immediately, with 400 staff, a portfolio of complex generics and a US manufacturing facility transferring to the Indian giant.
Generics Bulletin - July 2, 2026

Haleon Working On Switches, ‘Maybe’ In The US
Haleon's OTC head Kath Swallow says growth rests on backing brands properly, launching with discipline and making sure innovation lands in the market rather than adding for the sake of it. Switches remain in the pipeline, with a US move not ruled out.
HBW Insight - July 2, 2026

EU Expands MDR WET Exemption List
Over 70 additional well-established technologies will be exempt from clinical investigations, as the EU aims for more flexible and future-proof WET regulation.
Medtech Insight - July 2, 2026

People On The Move: Appointments At Haleon, Ceres, FSE
A round up of the latest moves in Europe's consumer health sector: Haleon names global head of commercial excellence; Ceres makes CEO change; Food Supplements Europe elects board members.
HBW Insight - July 2, 2026

Spinal Cord Stimulator Plaintiffs Allege Harm Far Beyond Device Failure
With more than 107,000 adverse event reports filed since 2016, spinal cord stimulators have drawn sharp legal scrutiny—and plaintiffs are alleging not just device failures but unlicensed medical practice by manufacturers' sales representatives.
Medtech Insight - July 2, 2026

Orca Dives Into Commercial Waters With FDA Approval For T-Cell Therapy Tregzi
Orca Bio has crossed from clinical-stage to commercial with FDA approval of Tregzi.
Scrip - July 2, 2026

Shift In US Kratom Policy To Scheduling 7-OH, Similar Derivatives Reaches DEA Notice
DEA files intent to temporarily place 7-OH and along with three other kratom derivatives into CSA Schedule after HHS Secretary Kennedy prioritized research leading to finding that the four substances have no accepted medical use and high potential for abuse.
HBW Insight - July 2, 2026

Takeda’s AI Strategy: ‘This Is More Than About Speed And Cost’
Scrip spoke with Takeda chief scientific officer Christopher Arendt about how the company is integrating artificial intelligence across its research functions and seeing early proof points from its AI collaborations with a focus on delivering high-quality molecules faster.
Scrip - July 2, 2026